Protirelin
Also known as: Lopremone, pGlu-His-Pro-NH2, Protirelin, Relefact TRH, Thypinone, Thyrotropin-releasing hormone, Thyrotropin‑releasing hormone, TRH
Source Protirelin at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Protirelin, also known as thyrotropin‑releasing hormone (TRH) analogue, is a synthetic peptide approved for prescription use, administered intravenously. It has been investigated as a neuro‑modulatory agent to aid recovery of consciousness after head trauma, improve cognitive function after stroke, reduce psychotic symptoms in schizophrenia, and as an adjunct in amyotrophic lateral sclerosis (ALS). Experimental work also explores its anticonvulsant potential.
Mechanism of Action
Protirelin mimics endogenous TRH, binding to TRH receptors in the central nervous system and pituitary. Activation of these G‑protein‑coupled receptors stimulates phospholipase C, raises intracellular calcium, and promotes release of downstream neuro‑transmitters such as acetylcholine, dopamine and serotonin. These actions are thought to enhance neuronal excitability, modulate synaptic plasticity, and influence endocrine axes (e.g., thyroid‑stimulating hormone release).
What the Research Shows
Clinical reports from Japan note protirelin tartrate (Hirtonin) as one of two drugs used to promote recovery of consciousness after head trauma. A double‑blind multicenter trial in 136 stroke patients reported improvements in attentiveness, learning and memory compared with placebo. In a crossover study of 17 schizophrenic patients, a single 0.5 mg IV dose reduced psychotic symptoms by about 50% with few side effects. ALS investigations have yielded conflicting outcomes, with animal data suggesting a gender‑dependent potentiation of reflexes that may have been overlooked in human trials. Pre‑clinical work demonstrates anticonvulsant effects in kindled seizure models, especially when delivered intranasally via biodegradable nanoparticles, though human seizure data are limited to isolated case reports.
Reported Benefits
Evidence from a randomized stroke trial suggests protirelin can enhance cognitive recovery. Small schizophrenia studies indicate a rapid, transient reduction in psychotic symptoms after IV dosing. Animal models and early human observations point to anticonvulsant activity, and gender‑specific benefits have been hypothesized for ALS. These findings support its potential as a neuro‑modulatory adjunct in various CNS disorders.
Limitations of the Evidence
Clinical data are limited in size and scope; the stroke trial, while double‑blind, involved only 136 participants, and schizophrenia data stem from a very small crossover study. ALS results are inconsistent and have not accounted for patient sex or hormonal status. The anticonvulsant effect is demonstrated mainly in rodent models and experimental nanoparticle delivery, with no robust human trials. Safety information is sparse, relying on occasional case reports of seizures and limited adverse‑event reporting.
Safety Considerations
In the schizophrenia study, side effects were comparable to niacin and considered infrequent. A 1990 drug‑safety review listed protirelin among agents with only occasional case reports of drug‑induced seizures, indicating a rare but possible pro‑convulsant risk, especially at high or unintended doses. Overall, systematic safety data are lacking, and clinicians should monitor for neurological changes and endocrine alterations during use.
How It Is Administered
Protirelin is approved for intravenous administration. Experimental investigations have also employed intranasal delivery of peptide‑loaded nanoparticles to bypass the blood‑brain barrier, but these routes are not part of the approved formulation.
Routes of Administration
Goals & Uses
- Diagnostic assessment of pituitary TSH reserveEndocrine DiagnosticsHigh
- Differentiation of hypothalamic vs. pituitary hypothyroidismEndocrine DiagnosticsHigh
- Neuroprotection / CNS disorders (investigational)NeurologyLow
- Prolactin secretion assessmentEndocrine DiagnosticsModerate
- Pituitary‑thyroid axis diagnostic testingDiagnosticHigh
Contraindications
- Known hypersensitivity to protirelinAllergy/ImmunologyHigh
- HyperthyroidismEndocrineHigh
- Seizure disordersNeurologyModerate
- Coronary artery disease (unstable)CardiovascularHigh
- Severe hypertensionCardiovascularModerate
- Myocardial infarction (recent)CardiovascularHigh
Adverse Effects
- Urge to urinateUrologicalCommon
- HeadacheNeurologicUncommonPain in the head or upper neck
- Transient hypertensionCardiovascularUncommon
- HypotensionCardiovascularRareLow blood pressure
- FlushingVascularCommonWarmth and redness of the skin
- NauseaGastrointestinalCommonFeeling of sickness or urge to vomit
- Flushing / warmth sensationVascularCommon
- Anxiety / lightheadednessNeurologicalUncommon
Drug Interactions
- Dopamine agonists (e.g., levodopa, bromocriptine)Moderate
- Antihypertensive agentsModerate
- CorticosteroidsModerate
- Antidepressants (tricyclics, SSRIs)Low
- Levothyroxine / thyroid hormoneHigh
Population Constraints
- PregnancyReproductive SafetyRelative
- Elderly patients with cardiovascular diseaseCardiovascularRelative
- Pediatric patientsAgeRelative
- Patients with adrenal insufficiencyEndocrineRelative
- Pregnant womenReproductiveRelative
Regulatory Status
- European UnionUnapprovedNot authorized for therapeutic use in the European Union.
- United StatesUnapprovedAvailable only for research and limited diagnostic use; not FDA‑approved as a drug.
- United KingdomUnapprovedNo marketing authorisation; used off‑label for diagnostic testing.
Not approved as a therapeutic agent in major jurisdictions; available as a research chemical and for limited diagnostic applications.
Evidence & Sources
- Journal ArticleModerateMaejima S, Katayama Y2001-01-01T00:00:00.000000Z
- Journal ArticleModerateZaccara G, Muscas GC, Messori A1990-01-01T00:00:00.000000Z
- Journal ArticleModerateFioravanti M1990-01-01T00:00:00.000000Z
- Journal ArticleModerateKubek MJ, Domb AJ, Veronesi MC2009-01-01T00:00:00.000000Z
- Journal ArticleModeratePrange AJ Jr, et al.1979-01-01T00:00:00.000000Z
- Journal ArticleModerateMiller SC, Warnick JE1989-01-01T00:00:00.000000Z
Frequently Asked Questions
What conditions has protirelin been studied for?
It has been examined as a recovery aid after head trauma, a cognitive enhancer in stroke sequelae, a rapid antipsychotic in schizophrenia, an adjunct in ALS, and an anticonvulsant in animal seizure models.
How is protirelin given to patients?
The approved formulation is administered intravenously; research settings have also used intranasal delivery of nanoparticle‑encapsulated peptide, which is not an approved route.
Are there any serious side effects?
Serious adverse events are rare; occasional case reports describe seizures, and a small schizophrenia trial reported side effects similar to niacin. Systematic safety data are limited.
Does protirelin work for all patients with ALS?
Clinical studies have shown mixed results, and animal data suggest efficacy may depend on sex and hormonal status, which has not been consistently addressed in human trials.
Is protirelin a cure for stroke‑related cognitive deficits?
A double‑blind trial showed modest improvements in attention, learning and memory, but evidence is limited to one study; it should be viewed as a potential adjunct, not a cure.
What is Protirelin?
Protirelin, also known as thyrotropin‑releasing hormone (TRH) analogue, is a synthetic peptide approved for prescription use, administered intravenously. It has been investigated as a neuro‑modulatory agent to aid recovery of consciousness after head trauma, improve cognitive function after stroke, reduce psychotic symptoms in schizophrenia, and as an adjunct in amyotrophic lateral sclerosis (ALS). Experimental work also explores its anticonvulsant potential.
What is Protirelin used for?
Protirelin is educationally associated with: Diagnostic assessment of pituitary TSH reserve, Differentiation of hypothalamic vs. pituitary hypothyroidism, Neuroprotection / CNS disorders (investigational), Prolactin secretion assessment, Pituitary‑thyroid axis diagnostic testing. Educational only — not medical advice.
How is Protirelin administered?
Recorded routes of administration: Intravenous, Subcutaneous.
What are the potential side effects of Protirelin?
Reported adverse effects include: Urge to urinate, Headache, Transient hypertension, Hypotension, Flushing, Nausea, Flushing / warmth sensation, Anxiety / lightheadedness. This list is not exhaustive — consult a qualified clinician.
Who should avoid Protirelin?
Recorded contraindications: Known hypersensitivity to protirelin, Hyperthyroidism, Seizure disorders, Coronary artery disease (unstable), Severe hypertension, Myocardial infarction (recent). Consult a qualified clinician before use.